



ISIN LU0069152568

As at 8 May 2025

UBS (Lux) Equity Fund - Biotech (USD) P-acc USD

Risk indicator (SRI)

1	2	3	4	5	6	7
← Lower risk					Higher risk →	
Source: fund management company				As at 14 February 2025		

Master data

Fund management company	UBS Asset Management (Europe) S.A.
Fund domicile	Luxembourg
Inception date	15 October 1996
ISIN	LU0069152568
Swiss security no.	512723
Fund currency	USD
Appropriation of income	accumulating
Ongoing charges under PRIIP KID as at 14 February 2025	2.11%
End of financial year	30 November
Fund volume as at 31 March 2025	USD 365.73m
Net asset value (NAV) as at 8 May 2025	600.37 USD

Performance (in fund currency)



	2019	2020	2021	2022	2023	2024
Performance p. a.	26.26%	24.61%	-5.63%	-8.31%	1.44%	-9.18%

Source: fund management company

As at 8 May 2025

Fund performance

	YTD	1 year	3 years	5 years	10 years	since inception
Performance p. a.	-	-12.28%	0.03%	-3.10%	-0.54%	6.47%
Cumulative performance	-7.81%	-12.28%	0.09%	-14.59%	-5.26%	500.37%
Volatility	27.93%	22.63%	22.61%	22.76%	24.82%	27.59%

Source: fund management company

As at 8 May 2025

Top holdings of fund volume (in %)

1. Vertex Pharmaceuticals, Inc.	10.03%
2. Alnylam Pharma	7.60%
3. ABBVIE INC.	5.98%
4. Gilead Sciences	5.46%
5. Neurocrine Bio	5.26%

Source: fund management company

As at 31 March 2025

Disclaimer: This is a marketing document. The statements herein are provided for information purposes only. They do not constitute an offer, investment advice or a recommendation to acquire or sell financial instruments or to conclude any other legal transactions. This document has been produced with the greatest possible care and to the best of our knowledge and belief. However, we provide no guarantee with regard to its content and completeness and do not accept any liability for losses which may arise from making use of this information. Past performance is not an indicator of current and future developments and results. The performance shown here has been calculated net of fees. It does not include any issuing commissions charged when purchases are made. The regulatory documentation for the collective investments contained in the portfolios (such as the prospectus, fund contract, key investor information document [KIID] or key information document and latest annual/half-year report) can be obtained free of charge in printed or electronic form from Swiss Life Asset Management Ltd, General-Guisan-Quai 40, 8002 Zurich, info@swisslife-am.com and from the applicable Swiss fund management and, for funds domiciled abroad, their respective representatives in Switzerland. You can obtain the ordering addresses and details of the fund management company, the representative, the payment office and the country of origin of the collective investment from Swiss Life Asset Management Ltd. The published information is intended exclusively for persons domiciled in Switzerland. The products and collective investments outlined here may not be acquired directly or indirectly by persons deemed to be US persons under US tax law or by persons who are subject to US tax law for any other reason, nor may they be transferred to them.